Phase I/II study of Carboplatin plus Nab-Paclitaxel in patients with advanced non-small-cell lung cancer and a performance status of 2
Latest Information Update: 15 Jul 2014
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Jul 2014 New trial record